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SUMMARY 
 
Good visual acuity requires that the axial length of the ocular globe is matched to the 
refractive power of the cornea and lens in order to focus the images of distant objects onto the 
retina. During the growth of the juvenile eye, this is achieved through the emmetropisation 
process that adjusts the ocular axial length to compensate for the refractive changes that occur 
in the anterior segment. A failure of the emmetropisation process can result in either 
excessive or insufficient axial growth, leading to myopia or hyperopia, respectively. 
Emmetropization is mainly regulated by the retina, which generates two opposite signals: 
‘GO/GROW’ signals to increase axial growth and ‘STOP’ signals to block it. The presence of 
‘GO/GROW’ and 'STOP’ signals was investigated by a proteomic analysis of the retinas 
from chicken with experimental myopia and hyperopia. Of 18 differentially expressed 
proteins that were identified, 5 display an expression profile corresponding to ‘GO/GROW’ 
signals and 2 correspond to ‘STOP’ signals. Western blotting confirmed that Apolipoprotein 
A1 (Apo A1) has the characteristics of a ‘STOP’ signal both in the retina as well as in the 
fibrous sclera. In accordance with this, intraocular application of the PPAR-alpha agonist 
GW7647 resulted in upregulation of Apo A1 levels and in a significant reduction of 
experimental myopia.  In conclusion, using a comprehensive functional proteomics analysis 
of chicken ocular growth models we identified targets for ocular growth control.  The 
correlation of elevated ApoA1 levels with reduced ocular axial growth points towards a 
functional relationship with the observed  morphological changes of the eye. 
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INTRODUCTION 
 
Axial eye growth is naturally controlled from infancy to early adulthood by a vision-
dependent mechanism (emmetropization) with the primary aim of matching the ocular axial 
length to the optical power (1). A failure of the emmetropization process can lead to myopia 
or to hyperopia. An excessive longitudinal growth of the ocular globe will place the focal 
plane of the eye in front of the retina: the eye is myopic or short-sighted. Conversely, an 
insufficient axial growth will place the focal plane of the eye behind the retina: the eye is 
hyperopic or far-sighted (1). Studies on experimental animal models have demonstrated that 
emmetropization is driven by visual inputs (2, 3, and 4) and primarily controlled by the retina 
(2, 4). The control of ocular axial growth by visual factors has been extensively investigated 
in chicken experimental models (3, 4). Applying negative lenses over the eye of the chicken 
places the focal plane behind the retina (hyperopic defocus), accelerates axial eye growth and 
leads to a myopic condition (Lens Induced Myopia, LIM). Conversely, applying positive 
lenses places the focal plane before the retina (myopic defocus), slows down axial eye growth 
and leads to a hyperopic condition (Lens Induced Hyperopia, LIH). In both cases, the size 
and shape of the eye are adjusted to compensate for the defocus and move the retina toward 
the focal plane. Moreover, applying light diffusers over the eye of the chicken induces a very 
robust axial growth referred to as Form Deprivation Myopia (FDM). 
 
According to a popular working hypothesis, originally formulated by Wallman (2), these 
signals can be divided in two categories: ‘GO/GROW’ signals that accelerate axial growth, 
and ‘STOP’ signals that prevent the growth. ‘GO/GROW’ signals are induced by negative 
lenses (hyperopic defocus) or form deprivation, while ‘STOP’ signals are induced by positive 
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lenses (myopic defocus). An excess of ‘GO/GROW’ signals or a defect of ‘STOP’ signals is 
thought to underlie the excessive longitudinal growth of the ocular globe observed in myopic 
subjects (1). The molecular substrate of ‘GO/GROW’ and ‘STOP’ signals has not been fully 
elucidated yet, but changes in gene and protein expression have been correlated with these 
signals (5). Phenotypically, the expression levels of a ‘STOP’ signal should be increased in 
response to myopic defocus (e.g. positive lenses) and an induction of this signal should 
reduce the excessive axial growth induced by experimental myopia. Conversely, the levels of 
a ‘GO/GROW’ signal should be increased in response to hyperopic defocus (e.g. negative 
lenses) or form deprivation and an induction of this signal should exacerbate the axial growth 
induced by experimental myopia. For instance, according to these criteria, the transcription 
factors Pax6 (6) and ZENK (7) display ‘GO/GROW’ and ‘STOP’ profiles, respectively. 
Furthermore, peptides like FGF-2 (8) or glucagon (9, 10) have been shown to function as 
‘STOP’ signals, whereas TGF-beta acts as a ‘GO/GROW’ signal (8, 11). In the case of 
glucagon both its activity and expression profile suggest it might be a ‘STOP’ signal, as its 
mRNA levels in the retina are increased by myopic defocus (10). In many cases reported so 
far, the expression profiles of putative ‘STOP’ and ‘GO/GROW’ signals have been assessed 
at the mRNA level (1, 5, 10), which is not always correlated with protein expression due to 
posttranscriptional regulatory mechanisms (12). In the current study, we looked 
systematically for proteins upregulated in response to myopic defocus and demonstrate Apo 
A1 to function as a ‘STOP’ signal by its capability to inhibit excessive ocular axial growth. 
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EXPERIMENTAL PROCEDURES 
This study was comprised of two parts, (i) a proteomic analysis (using 2D-PAGE, MALDI-
TOF-MS and -MSMS) of the retina and fibrous sclera of chicken that had been exposed to 
hyperopic or myopic defocus for either 1 or 7 days and (ii) an investigation of the effect on 
eye growth of injecting a peroxisome proliferator-activated receptor alpha agonist into the 
vitreous. Animals for use in part (i) were visually treated in Brisbane, Australia and ocular 
tissues sent to Basel, Switzerland for analysis. Part (ii) experiments were carried out at 
Tübingen, Germany. Experiments were conducted in accordance with the "Australian code of 
practice for the care and use of animals for scientific purposes" of the NHMRC and approval 
for this project was obtained from the University Animal Ethics Committees of the 
Queensland University of Technology and the University of Tuebingen. 
 
Sample preparation−10 days old male chicken (Rhode Island Red/Rhode Island White cross) 
were subjected to one of three different visual treatments: Form Deprivation with translucent 
goggles (n=30), Lens Induced Myopia (n=30) with negative lenses (-15 Diopters) and Lens 
Induced Hyperopia (n=30) with positive lenses (+15 Diopters). These treatments were 
applied monocular for either 1 or 7 days. Animals not given a specific visual treatment were 
included as controls (CTL group, n=15). At the end of the treatment period the eyes were 
obtained, the retinas and fibrous scleras were isolated in PBS and snap-frozen in liquid 
nitrogen. For 2D-electrophoretic separation, the frozen tissue was pooled and resuspended in 
Rabilloud buffer (13) at 7 retinas or 10 fibrous scleras per ml. After 20 min at room 
temperature, samples were centrifuged at 16’000 g for 20 min. Subsequently, the supernatant 
was withdrawn and stored at –80 °C. About 50 µl of this protein extract (approx. 10 mg/ml) 
was diluted twofold in 2x SDS-PAGE sample loading buffer (Invitrogen, Carlsbad, CA, 
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USA) in order to perform later Western blot analysis. For an independent set of samples, the 
tissues were not pooled but collected and analyzed individually by Western blot. 
2D-PAGE −Two-dimensional electrophoresis was carried out on narrow-range immobilized 
pH gradients (ultra zoom gels) according to Hoving et al. (13). For the first dimension, 
samples of approximately 0.5-1 mg protein were loaded onto the IPG strips (GE Healthcare, 
Piscataway, NJ, USA) by reswelling the strips in sample solution (14). Isoelectric focusing 
was performed on the Multiphor II apparatus (GE Healthcare, Piscataway, NJ, USA) for 
approximately 70 kVh at 20 °C, using the following voltage gradient: (i) 3 h 300 V, (ii) 5 h 
linear gradient from 300 to 3500 V and (iii) continue at 3500 V until target kVh. Five 
replicates of each sample were run on each of the four gradients. After focusing, IPG strips 
were equilibrated in equilibration buffer (6 M Urea, 2 % SDS, 50 mM Tris pH 8.8, 30 % v/v 
glycerol) with 2% DTT for 12 min in the first step and 5% iodoacetamide for 6 min in the 
second step (15). For the second dimension, IPG strips were applied to 20 x 25 cm (GE 
Healthcare, Piscataway, NJ, USA) SDS-PAGE gels (12 % T, 2.6 % C), which were run 
overnight at 20 mA/gel at 15 °C. The gels were stained overnight in Sypro Ruby (Molecular 
Probes, Eugene, OR, USA). 
Image and data analysis−The gel images were digitized as img files with the FLA-3000 
fluorescence imager (Fuji, provided by Raytest, Straubenhardt, Germany) using 473 nm 
excitation and a 520 nm high-pass emission filter. Where necessary, img files were converted 
to 16-bit TIFF files using the ‘Img2tiff’ program provided with the scanner (Raytest, 
Straubenhardt, Germany). Image analysis was carried out using the Progenesis Discovery 
package (Non-Linear Dynamics, Newcastle, UK). For each gradient, the analysis included 
three replicates for each of the eight groups: the controls and the three treatments (FDM, LIM 
and LIH) at two time points (1 day and 7 days of treatment). Spot volumes were normalized 
in each gel according to the ‘Match Ratio’ method. Spots were considered as differentially 
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expressed if there was at least a twofold difference of normalized expression level 
(normalized spot volume) with a p< 0.05 level (t-test) significance between control and any 
of the treatments. Since the digitized images sometimes contain artefacts, due to incomplete 
resolution of spots or background staining, differences were always checked and corrected, if 
necessary, by visual analysis of the original gels. The criterion to classify an expression 
profile as a ‘STOP’ profile was that the normalized expression level should be twofold higher 
in the hyperopic group (treated with +15 D lenses) than in the control group, and also higher 
than in the myopic groups (treated with -15 D lenses). An expression profile was classified as 
a ‘GO/GROW’ profile if the normalized expression level of one of the myopic groups was 
twofold higher than in the control group; also the expression levels for both myopic groups 
should be higher than for the control and hyperopic groups. 
In-gel trypsin digestion−For spot picking gels were prepared as above, but stained with 
colloidal Coomassie Blue G-250, using the method of Anderson (16). Spots of interest were 
excised and in-gel digested with modified porcine trypsin (Promega, Madison WI, USA) as 
described (17), using a microtiter plate format (CB080, Proxeon, Odense, DK). Spots were 
finally extracted with 5% formic acid. 
MALDI MS on PerSeptive Voyager Elite instrument−α-cyano-4-hydroxy-cinnamic 
acid/nitrocellulose matrices were prepared by a modified version of the fast evaporation 
technique of Jensen et al. (18). A solution of nitrocellulose in acetone (10 mg in 0.5 mL; 
Trans-Blot Transfer Medium, Bio-Rad, Glattbrugg, Switzerland) was admixed to a 
suspension of α-cyano-4-hydroxy-cinnamic acid in isopropanol (20 mg in 0.5 mL; Sigma, St. 
Louis, MO, USA). 0.5 μL of this solution was applied to the sample plate followed by 0.8 μL 
of sample solution in 15 % CH3CN/H2O/2% HCOOH corresponding to 5 % of total sample. 
Reflectron positive MALDI mass spectra were recorded on a PerSeptive Voyager Elite mass 
spectrometer (Framingham, MA, USA) at 20 kV accelerating potential in the delayed 
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extraction mode using standard settings for delay times and grid voltages. Samples were 
irradiated by a nitrogen laser pulse at 337 nm and 256 laser shots were summed. Spectra were 
in most cases calibrated internally on known background signals. 
MALDI-MS and MSMS on 4700 Proteomics Analyzer−Selected samples were analyzed using 
the Applied Biosystems 4700 Proteomics Analyzer (ABI, Framingham, MA, USA) in MS 
and MSMS mode. Tryptic hydrolysates were collected in a second microtiter plate and were 
purified on ZipTips (Millipore Corporation, Bedford, MA, USA) using a Tecan Genesis 
ProTeam 150 system (Tecan, Maennedorf, Switzerland). After washing with 2 x 5 μL 80 % 
ACN, 0.1 % TFA the tips were equilibrated with 2 x 5 μL 0.1 % TFA and the hydrolysate 
was applied; after washing with 4 x 5 μL 0.1 % TFA, peptides were directly eluted onto ABI 
4700 MALDI targets (100 well plates) with 2 μL of a solution of α-cyano-4-
hydroxycinnamic acid matrix (3 mg/mL in 50% ACN, 0.1 % TFA) applied to the backend of 
the ZipTips. Both MS and MSMS data were acquired with an Nd: YAG laser with 200 Hz 
repetition rate; 2000 shots were accumulated for spectra in MS mode and 4000 shots in 
MSMS mode. MSMS mode was operated with 1 keV and products of metastable 
decomposition at elevated laser power were detected. MS data were acquired with close 
external calibration and calibrated internally on trypsin background, MSMS data were 
acquired using default instrument calibration. 
Data base search−Initial searches were performed against release 19.08.2002 of the 
nonredundant NCBI database using the program PepSea (Proxeon, Odense, DK); a mass 
accuracy better than 80 ppm was expected for masses of tryptic peptides (1 missed cleavage 
allowed) and fitting signals were manually checked for adequate signal to noise. Generally, 
mean observed errors were less than 50 ppm. The minimum number of peptides required for 
a match was individually adjusted dependent on protein size and extent of background 
contributions. For identical proteins identified in different spots, less intense spectral patterns 
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were verified comparison with the most intense peptide mass fingerprint as reference. 
Recently, MS data searches were repeated against the UniRef_100 database (UniProt 
Reference Clusters, European Bioinformatics Institute, 24.8.2005), resulting in the 
identification of the hypothetical protein Q5ZML3_CHICK (UniProt ID), which had not been 
retrieved in the original search. In this case the Mascot program was used with an expected 
mass accuracy better than 80 ppm and with the possibility of one missed tryptic cleavage. 
Nano-electrospray MSMS− The sample leftover from the MALDI mass fingerprint analysis 
was concentrated/desalted on a needle (borosilicate capillary, Proxeon, Odense, DK) which 
was packed with ~ 100 nL of POROS R3 sorbent (ABI, Framingham MA, USA). In short: 
after loading the sample, a washing step with 12 µL of 2% formic acid in aqueous solution 
followed, then the peptide mixture was directly eluted into the spraying needle (gold-coated 
borosilicate capillary, Proxeon, Odense, DK) ) by the addition of 1-2 µL of 2:50:48 (v/v/v) 
HCOOH/CH3OH/H2O. The spraying process was started by applying a voltage difference 
(900 V) between the needle tip and the orifice (1.5-mm distance) of the ABI-Sciex QSTAR 
mass spectrometer (Toronto, Canada). A full mass spectrum was acquired over a wide mass 
range (m/z 350-2000), and parent ions (mass window of 2 Da) of interest were mass-selected 
and fragmented by collision-induced dissociation with nitrogen (collision energy was 
adjusted manually; collision gas pressure was set to 5 arbitrary units). 
Interpretation of MS and MS/MS spectra was performed manually in order to obtain a 
peptide sequence tag. The following database searches were performed with the program 
PepSea (Proxeon, Odense, DK); a mass accuracy better than 100 ppm was set for parent 
masses of tryptic peptides (1 missed cleavage allowed) and 0.1 Da for the fragment masses. 
The searches were performed against an EST database (08 Aug 2002, 5024497 entries). Once 
the protein sequence was identified (translated EST or combinations of ESTs), a combined 
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retrospective MALDI and nanoESMSMS analysis was performed in order to calculated the 
sequence coverage. 
Immunodetection of Apo A1−Standard Western blot procedure (19) was performed with an 
anti chicken Apo A1 polyclonal antibody (kindly provided by Prof. W. Schneider, University 
Departments at the Vienna Biocenter) at 1:10,000. Afterwards, the membranes were probed 
again either with a monoclonal anti-GAPDH antibody (Clone 6C5, Biodesign, Saco, ME, 
USA) or a polyclonal anti-Actin antibody (A2066, Sigma, St. Louis, MO, USA) at 1/10000 to 
obtain a loading control. 
Immunohistochemistry−Immunohistochemistry was performed on paraffin sections to study 
the expression level of Apo A1 on tissue sections within the eye. Primary anti-chicken Apo 
A1 antibodies were used at 1:1000 and revealed with an alkaline phosphatase-coupled 
secondary antibody using fast red. 
Intravitreal Injections−The experiments were started on day 8 post-hatching on three groups 
containing 7-8 animals. Daily injections were performed for 4 consecutive days in the 
vitreous of Male White Leghorn chicken (Gallus domesticus) under ether anaesthesia. 
Immediately after the first injection one eye was subjected to LIM treatment (–7 Diopters 
lenses) through the 4 days of the experiment. Animals of the LIM reference group received 
vehicle solution (70% saline + 30% DMSO) both in the LIM eye and its fellow contra lateral 
eye. The two other groups were treated with the peroxisome proliferator-activated receptor 
alpha agonist (PPAR-alpha) GW7647 (Sigma, Steinheim, Germany). For each group, the 
LIM eye was injected with doses of respectively 63 µg or 189 µg of GW7647 in 12.5 µl of 
vehicle solution while the fellow contra lateral eye received 12.5 µl of vehicle solution. The 
injections were performed with a 0.3 mm (30G) x 8 mm syringe cannula into the vitreous 
through skin, sclera, choroid and retina close to the margin of the upper orbit. 70% ethanol 
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was used to disinfect feathers and skin surrounding the injection site and to sterilize needles 
between injections. 
Ocular axial length measurements by A-scan ultrasonography−To measure axial ocular 
dimension, a modified low-frequency A-scan ultrasound biometer (Echorule, Phakosystems 
Inc., 3M, St. Paul, MN) with a transducer probe was used. The probe was designed for the 
human eye (20). Therefore its best spatial resolution was at about 2 cm from the transducer 
tip. To be able to measure chicken eyes the probe was elongated using a rubber tube (length 
12 mm, inner diameter 4 mm, outer diameter 6 mm) (9). The tube was filled with tap water 
and its tip covered with parafilm. Care was taken to avoid air bubbles being trapped in the 
tube. Measurements were performed in alert hand-held chicken. The cornea was locally 
anesthetized by one drop of a 2% Xylocain solution (AstraZeneca GmbH, Wedel, Germany). 
For measurements the tip of the rubber tube was moistened with the Xylocain solution and 
the cornea was touched for about one second. To determine the eye’s anterior chamber depth 
(ACD), lens thickness (LT), vitreous chamber depth (VCD) and axial length (AL) ultrasound 
traces were temporarily frozen. Axial length was defined as the distance from the corneal 
surface to the retino-vitreal interface, that is, the sum of ACD, LT and VCD. Measurements 
of axial length were performed before the first injection (baseline measurements) and after 
the 4-day treatment period. Three to four measurements were performed to determine the 
axial length of each eye. 
Data analysis−After the 4-day treatment period, the differences in axial length between the 
LIM treated eyes and their fellow contra lateral control eyes (interocular differences) were 
calculated. Subsequently the interocular differences were expressed in percentage values 
relative to the average intraocular difference value of the LIM reference group. The first step 
of the statistical analysis was to examine whether the interocular values of the three groups 
were homogeneous using an ANOVA test. Afterwards the differences between the LIM 
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reference group and the groups treated with GW7647 were examined post-hoc using 
Student’s t-test. 
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RESULTS 
 
List of proteins with ‘GO/GROW’ and ‘STOP’ profiles in the retina 
Our 2D gel analysis of retina samples revealed a limited number of consistent differences 
between the treatment groups: 37 of approximately 5000 spots that were analysed. across the 
four pH gradients These 37 protein species were analyzed by mass spectrometry and 30 were 
identified. Since some of the identified protein species were variants of the same protein, the 
30 identified spots corresponded to a total of 18 different proteins. Five of these displayed 
‘GO/GROW’ profiles and 2 had ‘STOP’ profiles (Table I), as illustrated with two examples 
of differentially expressed proteins (Fig. 1). Apo A1 displays a ‘STOP’ profile after 1 day 
and 7 days of treatment (Fig. 1A, 2B), as it is upregulated in the LIH group at both time 
points. The localisation of the differentially expressed Apo A1 protein species on the 2D gel 
is shown on Fig. 2. In contrast to this, vimentin displays a ‘GO/GROW’ profile after 1 day 
and 7 days of treatment (Fig. 1B, 2B), as it is upregulated in the FDM and LIM groups at 
both time points. Since our primary focus was on ‘STOP’ signals (see Introduction), Apo A1 
was selected for confirmation studies by antibody-based methods (in the absence of such 
tools for Q5ZML3_CHICK). 
Western Blot confirmation of the expression profile of Apo A1−Upregulation of Apo A1 in 
the chicken eye under conditions of myopic defocus could be confirmed on several sets of 
independent samples. The Western blot expression profile of Apo A1 in the retina after 1 day 
and 7 days of treatment (Fig. 3A) corresponds to the 2D gel analysis of the same samples 
(Fig. 1A) confirming the upregulation Apo A1 in the LIH groups after 1 day and 7 days of 
treatment. Moreover, Apo A1 is also upregulated in the sclera of the 1-day LIH group (Fig. 
3B). Since these data were derived from pooled samples, individual retinas of 3 control and 3 
15 
LIH animals were processed and analyzed separately after 1 day of treatment. Again, Apo A1 
levels are clearly increased in the LIH animals compared to the untreated controls (Fig. 3C). 
The three experiments confirmed that Apo A1 is upregulated in the hyperopic group. Our 
Western blot experiments consistently showed that two Apo A1 bands are detected in retina 
and fibrous sclera tissues at about 25 kD, both bands being increased in hyperopic animals. 
Further examination of the isoform distribution of Apo A1 by a 2D Western blot of a control 
retina sample revealed 2 isoforms of Apo A1 (Fig. 3D). Chicken Apo A1 is known to be 
transcribed as a 264 AA preproprotein which is subsequently processed in two steps, through 
a 246 AA pro-form into the 240 AA mature protein (21) with a concomitant shift to a more 
acidic pI.  The ApoA1 protein identified by mass spectrometry corresponds to the 240 AA 
mature form, as evidenced by the presence of  a minor peak in the peptide mass fingerprint of 
this spot matching the predicted N-terminal peptide of the mature form DEPQTPLDR 
(observed mass 1069.485, calculated monoisotopic mass 1069.5040).  
Validation of Apo A1 as a STOP signal −To validate Apo A1 as a functional ‘STOP’ signal, 
we used a PPAR-alpha agonist: GW7647. Compounds of this class are known to increase the 
expression levels of Apo A1 in a variety of tissues and cell types (22, 23). To ascertain that 
GW7647 is effective in our experimental model, it was injected intravitreously in myopic 
animals and the levels of Apo A1 in the eye were examined by immunohistochemistry using 
polyclonal anti ApoA1 antibodies as described by Tarugi et al. (24). Representative eye 
sections from vehicle-injected control (Fig. 4A) and LIM animals (Fig. 4B) show very similar 
Apo A1 expression patterns and levels, confirming our previous finding that the LIM 
treatment did not alter the levels of Apo A1. However, when animals subjected to LIM 
treatment (4 days of -7 Diopters lenses) were injected intravitreally with GW7647 ( Fig. 4C), 
the protein levels of Apo A1 were specifically increased in the fibrous sclera and the ganglion 
cell layer of vehicle injected animals (Fig. 4A and 4B). 
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Axial length measurements of Control and GW7647 treated eyes−Afterwards, we examined 
whether GW7647 could prevent the development of experimental myopia (LIM, 4 days of -7 
Diopters lenses). Three groups of LIM animals were injected with vehicle (n=7), 63 µg of 
GW7647 (n=8) or 189 µg of GW7647 (n=8). The interocular differences of axial length were 
calculated for the three treatment groups and expressed as percentages, with the vehicle-
injected LIM animals axial length data considered as the baseline degree of myopia. The 
average values of the three groups are represented as a bar graph in Fig. 5: myopia was 
reduced by about 30% in the GW7647 treated animals. A statistical analysis with the 
ANOVA test applied to the three groups revealed that the GW7647 had a significant effect 
(p<0.05). Post-hoc analysis, using Student’s t-test, showed that both doses of GW7647 
significantly reduced the development of experimental myopia (p<0.05 in both cases). 
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DISCUSSION 
 
The goal of the present study was to correlate the expression patterns of differentially 
expressed proteins with their potential functional role in the development of myopia. Using 
that concept, we identified 5 proteins (CRMP-62, B-creatine kinase, Gamma enolase, Tubulin 
alpha-1 chain and Vimentin) that display ‘GO/GROW’ profiles and 2 (Q5ZML3_CHICK and 
Apo A1) that display ‘STOP’ profiles. Interestingly, our findings do not overlap with 
previous reports on ‘GO/GROW’ or ‘STOP’ signals in myopia. A likely explanation is that 
the genes/protein reported previously (1) are classes of molecules (peptides, receptors and 
transcription factors) that are less accessible by 2D PAGE. Conversely, the soluble proteins 
represented in our 2D analysis had not been extensively investigated for their relation to 
myopia. We found that 3 out of the 5 proteins that display a ‘GO/GROW’ profile are related 
to cellular morphology: Vimentin and Tubulin alpha-1 chain are structural proteins, while 
CRMP-62 is involved in neuronal polarity (25). This is consistent with the morphological 
changes in the retina of myopic animals observed by Liang et al. (26). In the following 
subsections, we will first address a few points regarding the consistency of our results on Apo 
A1, followed by a discussion on the relevance of our findings and how they relate to a 
possible metabolic anomaly in myopia. 
 
Since Apo A1 is an abundant plasma protein, there is the possibility that its differential 
expression might be due to a plasma contamination of our samples. However, several 
observations argue against this explanation. First, in the event of a contamination, other 
abundant plasma proteins, such as albumin, should display the same profile in the retina as 
Apo A1, which was not the case according to our 2D gel analysis. Moreover, Apo A1 
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consistently displays a ‘STOP’ profile in several independent observations. In pooled retina 
samples, Apo A1 is upregulated in the hyperopic group after 1 and 7 days of treatment. In 
pooled fibrous sclera samples, Apo A1 is also upregulated in the hyperopic group after 1 day 
of treatment. Finally, in a set of individual retina samples, Apo A1 is clearly and consistently 
upregulated in the hyperopic eyes after 1 day of treatment. Taken together, these findings 
prove that the differential expression of Apo A1 is a reproducible and relevant observation. 
Western blot confirmations showed that two bands of Apo A1 are upregulated in the 
hyperopic animals. These two bands correspond to the two protein species that were resolved 
by 2D-PAGE Western blot, indicating that the two main Apo A1 species present in the retina 
are differentially expressed. Besides a detection problem, masking by stronger spot could also 
be the reason why only one of the two Apo A1 species was identified in the 2D gel-based 
differential analysis. 
 
We have shown that Apo A1 displays a ‘STOP’ profile both in the retina and the fibrous 
sclera, and that an upregulation of Apo A1 inhibits ocular axial elongation, which suggests 
that Apo A1 plays a role in the transmission of the ‘STOP’ signal. To our knowledge this is 
the first time that a candidate ‘STOP’ signal is identified with a protein expression profile 
that is consistent with its function. This further supports the notion that ‘GO/GROW’ and 
‘STOP’ signals are mediated at the protein level. Elucidation of the molecular signaling 
events upstream and downstream of Apo A1 will now be crucial to learn more about the 
etiology of myopia and to ultimately develop new therapeutic approaches (1). 
 
In the present study, we have shown that myopia can be reduced by a PPAR-alpha agonist: a 
class of compounds generally used to treat metabolic disorders (22) and known to act 
upstream of Apo A1 (23). PPAR-alpha agonists are in wide clinical use to manage several 
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types of dyslipidemias and prevent the associated risk of atherosclerosis and coronary artery 
disease (22) by raising HDL and lowering triglycerides levels (22). The effects of the PPAR-
alpha agonists on HDL metabolism are thought to occur through transcriptional mechanisms 
that increase the expression of Apo A1, the major protein constituent of the HDL lipoproteins 
(23). Interestingly, myopia has been associated (27, 28) with a condition that is treated with 
PPAR-alpha agonists (22): the pre-insulin-resistant state known as the metabolic syndrome or 
Syndrome X (28). PPAR-alpha agonists have been used in several clinical studies to improve 
the dyslipidemic profile observed in the metabolic syndrome (22): low HDL and 
hypertriglyceridemia (29). As we have shown that myopia can be reduced by a compound 
that acts on lipid and lipoprotein metabolism (22, 23), it is tempting to speculate that myopia 
might be associated with a metabolic disturbance as suggested by Cordain et al. (27, 28). 
Several mediators in pathways involved in metabolic disorders have also been associated 
with myopia: Insulin (1, 27), Glucagon (9, 10, 30), Nitric Oxide (1, 31, 32), TGF-beta (11, 
33), Plasminogen (11, 32), Retinoic Acid (1, 27). A systemic disturbance in the regulation of 
these pathways could impair the emmetropization process and promote the development of 
myopia. According to Cordain et al. (27, 28), the increased incidence of myopia in many 
countries is associated to high-glycemic-load western diets and hyperinsulinaemia. In this 
respect, Apo A1 seems to be a good candidate to link myopia to environmental conditions 
and metabolic disorders. Remarkably, insulin is known to regulate the expression of two 
transcription factors involved in myopia: Pax6 (34) and ZENK (35). Furthermore, the 
expression of ZENK is regulated both by insulin and glucose levels (35) and, in turn, ZENK 
acts upstream of Apo A1 (36). It would be interesting to investigate whether some 
components of this cascade are active within the retina. 
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Other signaling cascades that could play a role in modulating ocular axial growth 
downstream of Apo A1 include the plasminogen (11) and Wnt (37) pathways. Chicken Apo 
A1 is found in several types of lipoprotein particles (24) that have been reported to inhibit the 
plasminogen pathway: HDL, VLDL and LDL (38, 39). Plasminogen activation acts as a 
‘GO/GROW’ signal by processing latent TGF-beta to its active form (11). Plasminogen also 
activates the matrix metalloproteinases (40), which play an important role in experimental 
myopia (41). Apo A1 could act as a ‘STOP’ signal by inhibiting the plasminogen pathway, 
thereby preventing the activation of TGF-beta and matrix metalloproteinases (MMP). In the 
chicken, Apo A1 could also modulate plasminogen activation through the low density 
lipoprotein receptor (LDLR) family (42). An important point to mention is that chicken Apo 
A1 is considered the functional equivalent of both mammalian Apo A1 and Apo E (43), as 
Apo E is not expressed in avians (44). Therefore, in the chicken Apo A1 takes over the 
function of mammalian Apo E as a ligand for the receptors of the LDLR family, like LRP 
that regulates plasminogen and MMP activation (45). Several members of the LDLR family 
are involved in the development of the central nervous system: megalin, VLDLR and 
ApoER2 (46). Furthermore, LRP5 and LRP6 function as coreceptors for Wnt signal 
transduction (36) and are important for the development of the eye (47, 48). For instance, 
mouse embryos homozygous for an insertion mutation in the Lrp6 gene exhibit 
microphthalmia (47). A recent genetic study has shown that MFRP, a Frizzled-related 
protein, is important for the control of ocular axial length (49), which further suggests an 
involvement of the Wnt pathway. 
 
Based on our observations and on the discussed literature data, the role of Apo A1 in the 
regulation of emmetropia seems to be worthy of further investigation. More specifically, we 
propose that the signaling position of Apo A1 downstream of metabolic events and upstream 
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of apolipoprotein receptors involved in signaling pathways might be relevant to myopia. To 
test this hypothesis we will need to learn more about the function, the receptors and the 
metabolism of apolipoproteins in the eye. Moreover, as the metabolism of Apo A1 
significantly differs in avians and mammals, it is important to find out how our discovery in 
chicken translates to human refractive disorders. 
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FIGURE LEGENDS 
 
Fig. 1. Examples of protein that display profiles corresponding to ‘GO/GROW’ and 
‘STOP’ signals. A) Example of ‘STOP’ profile: normalized spot volume profile of Apo A1 
in the retina across the 8 indicated groups, error bars represent the Standard Deviation of the 
groups. B) Example of ‘GO/GROW’ profile: normalized spot volume profile of Vimentin in 
the retina across the 8 indicated groups, error bars represent the Standard Deviation of the 
groups. Y axis depicts normalized intensities, CTL = control, FDM = form deprivation 
myopia, LIM = lens induced myopia, LIH = lens induced hyperopia, * indicates significant 
differences as described under Experimental Procedures. 
 
Fig. 2. Differential expression of Apo A1 and Vimentin on 2D gels. A)Localisation of the 
differentially expressed Apolipoprotein A1 protein species on a retina extract 2D gel in the 
4.5-5.5 pH range. B) Zoomed out inserts of differentially expressed Apolipoprotein A1 (right 
panel) and Vimentin protein (left panel) species on retina extract 2D gels, the groups and time 
points are indicated on the figure, CTL = control, FDM = form deprivation myopia, LIH = 
lens induced hyperopia. 
 
Fig. 3. Western blot confirmation that Apo A1 levels are increased in hyperopic animals 
A) Confirmation of the expression profile of Apo A1 in pooled retina samples by Western 
blot, using GAPDH as a loading control. B) Expression profile of Apo A1 in pooled fibrous 
sclera samples by Western blot, using Actin as a loading control. C) Western blot 
confirmation that Apo A1 levels are increased in individual retina samples of hyperopic 
animals, using GAPDH as a loading control. The groups and time points corresponding to 
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each lane are indicated on the figure. D) Localisation of the Apo A1 isoforms on a 2D gel by 
Western blot. The pH and Molecular Weight ranges are indicated. 
 
Fig. 4. The PPAR-alpha agonist, GW7647, increases the levels of Apo A1 in the retina 
and the fibrous sclera. Apo A1 protein levels were examined on tissue sections A-C) by 
immunohistochemistry using fast red staining. A) Representative eye section of a control 
animal injected with vehicle; the positions of the retina, choroid and sclera are indicated. B) 
Representative eye section of an animal treated with -7D lens and injected with vehicle; the 
positions of the fibrous sclera and ganglion cell layer are indicated C) Representative eye 
section of an animal treated with -7D lens and injected with 189 µg of GW 7649. Apo A1 
levels are specifically increased in the fibrous sclera and ganglion cell layer. The diffuse 
staining in the choroids section is attributed to circulating ApoA1 as there was no detectable 
signal with the secondary antibody alone (not shown) 
 
Fig. 5. The PPAR-alpha agonist, GW7647, reduces experimentally induced myopia. The 
effect of 63 µg and 189 µg intravitreal injections of GW7647 on the ocular axial length of 
LIM animals is shown: both the 63 µg ( n=8) and 189 µg injections (n=8) of GW7647 
significantly reduce myopia as compared to control (n=7). (* indicates that a group is 
significantly different from the controls with p<0.05 using Students t-test ) 
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Table 1. List of differentially expressed Spots that display ‘STOP’ or ‘GO/GROW’ 
profiles on retina 2D Gels of control, myopic and hyperopic animals. 
The essential characteristics of the selected spots are listed in the table: final Identification of 
the spot along with its Swissprot accession number, number of isoforms identified, observed 
Molecular Weight for each isoform, calculated Molecular Weight, observed isoelectric point 
for each isoform, calculated isoelectric point and type of expression pattern. 
Protein Name and 
Accession number 
Number of 
isoforms 
Obs. 
MW 
 kDa 
Calc. 
MW 
Da 
Obs. 
pI 
Calc. 
pI 
Type of 
expression 
profile 
Apolipoprotein AI 
P08250 
1 
24 28808 5.2 5.31 
STOP 
Hypothetical protein 
Q5ZML3 
1 
33 28157 5.15 6.46 
STOP 
CRMP-62 
Q90635 
2 
55 
55 
62730 5.8 
5.85 
6.34 
GO/GROW 
B-creatine kinase 
P05122 
3 
42 
42 
41 
42553 5.8 
5.9 
6.2 
6.11 
GO/GROW 
Gamma enolase 
O57391 
1 
38 47651 4.6 4.68 
GO/GROW 
Tubulin alpha-1 
chain, fragment 
P02552 
1 
40 46414 5.1 4.82 
GO/GROW 
Vimentin 
P09654 
6 
40 
45 
40 
42 
42 
20 
53200 4.4 
4.4 
4.5 
4.6 
4.7 
4.35 
4.92 
GO/GROW 
 
